eamdacademy.org-8bOp-1792286429-v509528480 1792286429 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2024 3 1 Michael Turner Sophia Nguyen David Clark Emma Wilson 2024 10.68159/v509528480 https://eamdacademy.org/pub/journal/3/article/v509528480 Lawrence XY, Kopcha M. The future of pharmaceutical quality and the path to get there. Int J Pharm. 2017;528(1-2):354-9. Grangeia HB, Silva C, Simoes SP, Reis MS. Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives. Eur J Pharm Biopharm. 2020;147:19-37. Mishra V, Thakur S, Patil A, Shukla A. Quality by design (QbD) approaches in current pharmaceutical set-up. Expert Opin Drug Deliv. 2018;15(8):737-58. Vanhoorne V, Vervaet C. Recent progress in continuous manufacturing of oral solid dosage forms. Int J Pharm. 2020;579:119194. Vargas JM, Nielsen S, Cárdenas V, Gonzalez A, Aymat EY, Almodovar E, et al. Process analytical technology in continuous manufacturing of a commercial pharmaceutical product. Int J Pharm. 2018;538(1-2):167-78. Nagy B, Galata DL, Farkas A, Nagy ZK. Application of artificial neural networks in the process analytical technology of pharmaceutical manufacturing—a review. AAPS J. 2022;24(4):74. Arden NS, Fisher AC, Tyner K, Yu LX, Lee SL, Kopcha M. Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. Int J Pharm. 2021;602:120554. Pauli V, Roggo Y, Pellegatti L, Trung NQ, Elbaz F, Ensslin S, et al. Process analytical technology for continuous manufacturing tableting processing: A case study. J Pharm Biomed Anal. 2019;162:101-11. Roggo Y, Pauli V, Jelsch M, Pellegatti L, Elbaz F, Ensslin S, et al. Continuous manufacturing process monitoring of pharmaceutical solid dosage form: A case study. J Pharm Biomed Anal. 2020;179:112971. Nagy B, Szabados-Nacsa Á, Fülöp G, Nagyne AT, Galata DL, Farkas A, et al. Interpretable artificial neural networks for retrospective QbD of pharmaceutical tablet manufacturing based on a pilot-scale developmental dataset. Int J Pharm. 2023;633:122620. Malheiro V, Duarte J, Veiga F, Mascarenhas-Melo F. Exploiting pharma 4.0 technologies in the non-biological complex drugs manufacturing: innovations and implications. Pharmaceutics. 2023;15(11):2545. Shang C, You F. Data analytics and machine learning for smart process manufacturing: Recent advances and perspectives in the big data era. Engineering. 2019;5(6):1010-6. Reis MS, Gins G. Industrial process monitoring in the big data/industry 4.0 era: From detection, to diagnosis, to prognosis. Processes. 2017;5(3):35. Ge Z, Song Z, Ding SX, Huang B. Data mining and analytics in the process industry: The role of machine learning. IEEE Access. 2017;5:20590-616. Domokos A, Nagy B, Szilágyi B, Marosi G, Nagy ZK. Integrated continuous pharmaceutical technologies—a review. Org Process Res Dev. 2021;25(4):721-39. Jiménez-Luna J, Grisoni F, Schneider G. Drug discovery with explainable artificial intelligence. Nat Mach Intell. 2020;2(10):573-84. Barredo Arrieta A, Díaz-Rodríguez N, Del Ser J, Bennetot A, Tabik S, Barbado A, et al. Explainable artificial intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI. Inf Fusion. 2020;58:82-115. Adadi A, Berrada M. Peeking inside the black-box: a survey on explainable artificial intelligence (XAI). IEEE Access. 2018;6:52138-60. Holzinger A, Langs G, Denk H, Zatloukal K, Müller H. Causability and explainability of artificial intelligence in medicine. WIREs Data Min Knowl Discov. 2019;9(4):e1312. Amann J, Blasimme A, Vayena E, Frey D, Madai VI, Precise4Q Consortium. Explainability for artificial intelligence in healthcare: a multidisciplinary perspective. BMC Med Inform Decis Mak. 2020;20(1):310. Wiens J, Saria S, Sendak M, Ghassemi M, Liu VX, Doshi-Velez F, et al. Do no harm: a roadmap for responsible machine learning for health care. Nat Med. 2019;25(9):1337-40. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019;17(1):195. Lee SH, Kim JK, Jee JP, Jang DJ, Park YJ, Kim JE. Quality by Design (QbD) application for the pharmaceutical development process. J Pharm Investig. 2022;52(6):649-82. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-77. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24(3):773-80. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. In: Hock FJ, Gralinski MR, editors. Drug discovery and evaluation: safety and pharmacokinetic assays. 2nd ed. Cham: Springer; 2024. p. 1461-98. Dara S, Dhamercherla S, Jadav SS, Babu CM, Ahsan MJ. Machine learning in drug discovery: a review. Artif Intell Rev. 2022;55(3):1947-99. Benjamens S, Dhunnoo P, Meskó B. The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database. NPJ Digit Med. 2020;3(1):118. Muehlematter UJ, Daniore P, Vokinger KN. Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015–20): a comparative analysis. Lancet Digit Health. 2021;3(3):e195-203. Sharma D, Patel P, Shah M. A comprehensive study on Industry 4.0 in the pharmaceutical industry for sustainable development. Environ Sci Pollut Res. 2023;30(39):90088-98. McDermott O, Wojcik AM, Trubetskaya A, Sony M, Antony J, Kharub M. Pharma industry 4.0 deployment and readiness: a case study within a manufacturer. TQM J. 2024;36(9):456-76.